A Delaware District Court on Wednesday sided with Roivant subsidiary Arbutus Biopharma and Genevant Sciences in their ongoing patent infringement case against Moderna regarding the lipid nanoparticle delivery system used in the latter’s COVID-19 vaccine.
Genevant Sciences to Collaborate with Tome Biosciences
Genevant Sciences could be in line for over $114 million as part of a deal to combine its lipid nanoparticle tech with Tome Biosciences’ programmable genomic integration (PGI) expertise to develop an in vivo gene editing treatment for a rare liver disorder.
VANCOUVER, British Columbia, and BASEL, Switzerland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and an expansive lipid...
VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust and expansive...
Agreement provides nonexclusive access to Genevant’s leading LNP technology for use with Gritstone bio’s self-amplifying RNA technology in wide array of infectious disease vaccines Multi-year,...
March 10 (Reuters) - Despite the backing of the U.S. government, Moderna Inc (MRNA.O) on Friday failed to persuade a federal judge it should not have to face a patent lawsuit over its COVID-19 vaccine and that the United States should have been sued instead.
Feb 15 (Reuters) - The U.S. government should face a patent lawsuit over COVID-19 vaccines, not vaccine maker Moderna Inc (MRNA.O), the Department of Justice told a Delaware federal court on Tuesday.
Moderna's motion to dismiss a patent infringement lawsuit fell short after the company argued that the case should be directed at the U.S. government.
In its COVID-19 vaccine patent kerfuffle with Arbutus Biopharma and Roivant’s Genevant Sciences, mRNA hot shot Moderna aims to shield itself with its government contract, court documents filed Friday show.